

Global Vasculitis Drugs and Companies Pipeline Review H1 2016

Vasculitis Treatment Pipeline Review H1 2016

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- Summary

'[Vasculitis](#) - Pipeline Review, H2 2016', provides an overview of the Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/619264-vasculitis-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
- The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vasculitis

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619264-vasculitis-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619264-vasculitis-pipeline-review-h2-2016>

Key points in table of content

Table of Contents

Table of Contents	2
List of Tables	5
List of Figures	6
Introduction	7
Global Markets Direct Report Coverage	7
Vasculitis Overview	8
Therapeutics Development	9
Pipeline Products for Vasculitis - Overview	9
Pipeline Products for Vasculitis - Comparative Analysis	10
Vasculitis - Therapeutics under Development by Companies	11
Vasculitis - Therapeutics under Investigation by Universities/Institutes	12
Vasculitis - Pipeline Products Glance	13
Late Stage Products	13
Clinical Stage Products	14
Early Stage Products	15
Unknown Stage Products	16
Vasculitis - Products under Development by Companies	17
Vasculitis - Products under Investigation by Universities/Institutes	18
Vasculitis - Companies Involved in Therapeutics Development	19
AnGes MG, Inc.	19
ChemoCentryx, Inc.	20
Cipla Ltd.	21
Coherus BioSciences, Inc.	22
F. Hoffmann-La Roche Ltd.	23
GlaxoSmithKline Plc	24
Hemostemix Ltd	25
Johnson & Johnson	26
K-Stemcell Co., Ltd.	27
Panacea Biotec Limited	28
Pfizer Inc.	29
Sandoz International GmbH	30
Teijin Pharma Limited	31
Vasculitis - Therapeutics Assessment	32
Assessment by Monotherapy Products	32
Assessment by Target	33
Assessment by Mechanism of Action	35
Assessment by Route of Administration	37
Assessment by Molecule Type	39
Drug Profiles	41
ACP-01 - Drug Profile	41
Product Description	41
Mechanism Of Action	41
R&D Progress	41

belimumab - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

bepermingene perplasmid - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CCX-168 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

immune globulin (human) - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis -

Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

PF-1355 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

rituximab biosimilar - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

rituximab biosimilar - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

rituximab biosimilar - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

sirukumab - Drug Profile 68

Product Description 68

Mechanism Of Action 68
R&D Progress 68
Stem Cell Therapy for Thromboangiitis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Stempeucel - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tocilizumab - Drug Profile 76
Product Description 76
Mechanism Of Action 76

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619264

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342336451>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.